ImmunoGen Transitions To Commercial Stage With Elahere Launch

The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.

applause — ImmunoGen's first wholly owned drug was approved by FDA • Source: Shutterstock

More than 30 years after the company was established, ImmunoGen, Inc. is transitioning from an antibody-drug conjugate (ADC) developer into a commercial-stage company with the US Food and Drug Administration approval and upcoming launch of the company's first independently owned drug, Elahere (mirvetuximab soravtansine).

The approval comes following a long road for ImmunoGen, which first raised venture capital funding in 1988 with the goal...